Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Summary

The leading risk factor for corneal transplant rejection is abnormal blood vessel growth of the host bed. Vascular endothelial growth factor (VEGF) is thought to be a mediator of this corneal neovascularization (NV), therefore we would like to test the safety and efficacy of local VEGF blockade in the promotion of graft survival in high risk corneal transplants.

Timeline

Start

2009-12

Primary completion

2015-01

Completion

2015-01

Drugs

Indications